Novel, non-C481 BTK mutations have been described, including BTK L528W, which has been reported in patients treated with ibrutinib, zanubrutinib, and pirtobrutinib (Maddocks, JAMA Oncol. This is the largest dataset characterizing the incidence and patterns of BTK and PLCG2 mutations in patients with CLL treated with ibrutinib. BTK C481 mutations are the most frequently occurring mutations. PLCG2 mutations occur across the gene at a low incidence per locus (<5%).

over 1 year ago

Retrospective data

TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus) • PLCG2 (Phospholipase C Gamma 2)

TP53 mutation • BTK C481S • PLCG2 mutation • BTK mutation • BTK C481 • BTK C481R • BTK C481Y • BTK R665W • BTK T474I • BTK L845F • PLCG2 D1140N • PLCG2 L845F

Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Jaypirca (pirtobrutinib)